Advertisement

Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial

  • Sanjeev Kumar JhaEmail author
  • Manish K. Mishra
  • Kuldeep Saharawat
  • Praveen Jha
  • Shubham Purkayastha
  • Ravish Ranjan
Original Article
  • 29 Downloads

Abstract

Introduction

Resistance to commonly used antibiotics against Helicobacter pylori (H. pylori) is increasing rapidly leading to lower success of traditional triple therapy to eradicate H. pylori infection. So, search for a new regimen as the first-line therapy of H. pylori infection is needed.

Aim

In this study, we compared the efficacy of 14-day concomitant therapy and 14-day triple therapy for the eradication of H. pylori infection.

Method

In this open-labeled prospective trial, patients with H. pylori infection were randomized to concomitant therapy (pantoprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily in divided doses) and triple therapy (pantoprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses). Duration of treatment was 14 days. Gastric biopsy was done 10–12 weeks after completion of therapy to confirm H. pylori eradication.

Result

The eradication rate achieved with the concomitant therapy was significantly greater than that obtained with the triple therapy. Per-protocol eradication rates of concomitant and triple therapy were 77% and 58.3% (p = 0.028), respectively. Intention-to-treat eradication rates of concomitant and triple therapy were 70.1% and 49.3% (p = 0.013), respectively. Both the treatment regimens were well tolerated.

Conclusion

Although the rate of eradication of H. pylori infection with  concomitant therapy was higher than that with triple therapy, the rate of concomitant therapy was still less than expected.

Keywords

Antibiotics Helicobacter pylori Human pathogen 

Notes

Compliance with ethical standards

Conflict of interest

SKJ, MKM, KS, PJ, SP, and RR declare that they have no conflict of interest.

Ethics statement

The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclaimer

The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, or the printer/publishers are responsible for the results/findings and content of this article.

References

  1. 1.
    Talebi A, Abadi B, Kusters JG. Management of Helicobacter pylori infections. BMC Gastroenterol. 2016;16:94.CrossRefGoogle Scholar
  2. 2.
    Adlekha S, Chadha T, Krishnan P, Sumangala B. Prevalence of helicobacter pylori infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in Kerala, India. Ann Med Health Sci Res. 2013;3:559–63.CrossRefGoogle Scholar
  3. 3.
    Sodhi JS, Javid G, Zargar SA, et al. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol. 2013;28:808–13.Google Scholar
  4. 4.
    Thirumurthi S, Graham DY. Helicobacter pylori infection in India from a western perspective. Indian J Med Res. 2012;136:549–62.Google Scholar
  5. 5.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.CrossRefGoogle Scholar
  6. 6.
    Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374:1449–61.CrossRefGoogle Scholar
  7. 7.
    Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10:495–500.CrossRefGoogle Scholar
  8. 8.
    Malfertheiner P, Mégraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV Florence Consensus Report. Gut. 2012;61:646–64.Google Scholar
  9. 9.
    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51–69.Google Scholar
  10. 10.
    Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–600.Google Scholar
  11. 11.
    Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88:33–45.CrossRefGoogle Scholar
  12. 12.
    Gehlot V, Mahant S, Mukhopadhyay AK, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Resist. 2016;5:51–6.Google Scholar
  13. 13.
    Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol. 2014;32:408–13.CrossRefGoogle Scholar
  14. 14.
    Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol. 2003;18:1373–8.Google Scholar
  15. 15.
    Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.Google Scholar
  16. 16.
    Yeo YH, Shiu S-I, Ho HJ, et al. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2017;67:20–7.Google Scholar
  17. 17.
    Roy AD, Deuri S, Dutta UC. The diagnostic accuracy of rapid urease biopsy test compared to histopathology in implementing “test and treat” policy for Helicobacter pylori. Int J Appl Basic Med Res. 2016;6:18–22.CrossRefGoogle Scholar
  18. 18.
    Uotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3:9.Google Scholar
  19. 19.
    Sharma S, Mittal G, Agarwal RK, Ahuja V, Gupta R, Ahmad S. Comparison of different diagnostic methods of Helicobacter pylori in dyspeptic patients of a tertiary care hospital of Uttarakhand, India. Natl J Lab Med. 2016;5:MO06–10.Google Scholar
  20. 20.
    Choudhury G, Mohindra S. Epidemiology of Helicobacter pylori in India. Indian J Gastroenterol. 2000;19 Suppl 1:S3–6.Google Scholar
  21. 21.
    Lee HJ, Kim JI, Lee JS, et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol. 2015;21:351–9.Google Scholar
  22. 22.
    Lin L-C, Hsu T-H, Huang K-W, Tam K-W. No bismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: a meta-analysis of randomized controlled trials. World J Gastroenterol. 2016;22:5445–53.CrossRefGoogle Scholar
  23. 23.
    Kumar D, Ahuja V, Dhar A, Sharma MP. Randomized trial of a quadruple-drug regimen and a triple-drug regimen for eradication of Helicobacter pylori: long-term follow-up study. Indian J Gastroenterol. 2001;20:191–4.Google Scholar
  24. 24.
    Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J Gastroenterol. 2003;22:85–7.Google Scholar
  25. 25.
    Das R, Sureshkumar S, Sreenath GS, Kate V. Sequential versus concomitant therapy for eradication of helicobacter pylori in patients with perforated duodenal ulcer: a randomized trial. Saudi J Gastroenterol. 2016;22:309–15.CrossRefGoogle Scholar
  26. 26.
    Ashokkumar S, Agrawal S, Mandal J, Sureshkumar S, Sreenath GS, Kate V. Hybrid therapy versus sequential therapy for eradication of Helicobacter pylori: a randomized controlled trial. J Pharmacol Pharmacother. 2017;8:62–7.CrossRefGoogle Scholar
  27. 27.
    Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013;4:23–7.CrossRefGoogle Scholar
  28. 28.
    Nasa M, Choksey A, Phadke A, Sawant P. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study. Indian J Gastroenterol. 2013;32:392–6.CrossRefGoogle Scholar
  29. 29.
    Javid G, Zargar SA, Bhat K, et al. Efficacy and safety of sequential therapy versus standard triple therapy in Helicobacter pylori eradication in Kashmir India: a randomized comparative trial. Indian J Gastroenterol. 2013;32:190–4.Google Scholar
  30. 30.
    Heo J, Jeon SW, Jung JT, et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis. 2014;46:980–4.Google Scholar
  31. 31.
    Georgopoulos S, Papastergiou V, Xirouchakis E, et al. Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication. A randomized trial. J Clin Gastroenterol. 2013;47:228–32.Google Scholar
  32. 32.
    Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M. Quadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection. Med Clin (Barc). 2016;147:199–201.CrossRefGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyIndira Gandhi Institute of Medical SciencesSheikhpura, PatnaIndia

Personalised recommendations